Trial Profile
A study to investigate correlation between erlotinib and presence of epidermal growth factor receptor (EGFR) mutations, in Chinese patients with non-small cell lung cancer (NSCLC) who had failed first-line chemotherapy
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 15 Oct 2015
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 15 Oct 2015 New trial record